<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237419</url>
  </required_header>
  <id_info>
    <org_study_id>EASIC 30505</org_study_id>
    <nct_id>NCT00237419</nct_id>
  </id_info>
  <brief_title>Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis</brief_title>
  <official_title>An Open Label Extension, Investigator Initiated Trial to Examine Radiographic Progression , Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis. EASIC (European Ankylosing Spondylitis Infliximab Cohort)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rheumazentrum Ruhrgebiet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trial Coordination Center, 9713 GZ Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rheumazentrum Ruhrgebiet</source>
  <brief_summary>
    <textblock>
      Ankylosing spondylitis (AS) is a chronic inflammatory disease that involves the sacroiliac
      joints, axial skeleton, entheses and peripheral joints. Current therapy for AS is mainly
      NSAIDs and physiotherapy which are oft insufficient. Treatment with the TNF-alpha blocking
      agent infliximab was shown to have definite clinical efficacy in patients with active AS on a
      short- and a long-term-basis over 2 years. We want to show that treatment with infliximab on
      a long-term basis over 4 years is safe and efficient and can prevent radiographic progression
      over a long period of time. Further we want to learn about the outcome after discontinuation
      of anti-TNF-alpha therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown etiology that
      involves the sacroiliac joints, axial skeleton, entheses and peripheral joints. Chronic
      inflammation of entheses leads to new bone formation, syndesmophytes and ankylosis of joints,
      primarily in the axial skeleton. This leads to a dramatic loss of range of motion and to
      disability. The disease may also have nonskeletal manifestations including uveitis, carditis,
      pulmonary fibrosis and cardiac conduction abnormalities.

      Current therapy for AS is mainly with NSAIDs and physiotherapy which are often insufficient.
      Clinical outcome with conventional therapies has not been good, with 50-70% of patients
      progressing to fusion of the spine by 10 to 15 years. Treatment with the TNF-alpha blocking
      agent infliximab was shown to have definite clinical efficacy in patients with active
      ankylosing spondylitis on a short- and a long-term basis over 2 years.

      There is limited data available on the efficacy and safety of long-term anti-TNF therapy for
      3 and more years, the outcome after discontinuation of anti-TNF therapy and the effect of
      anti-TNF therapy on radiographic progression over a long period of time.

      The ASSERT trial was a 2 year international randomized placebo controlled trial to evaluate
      the efficacy and safety ot treatment with infliximab in patients with active and severe AS.
      The EASIC trial is initiated to follow the European participants of the ASSERT trial for at
      least an additional 2 years of treatment combined with systematic data collection.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2005</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of structural damage (radiographic progression)after 4 and 6 years of infliximab therapy (2 years of ASSERT trial plus 2 years of EASIC trial)</measure>
    <time_frame>November 2008 and November 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients which have received anti-TNF-alpha therapy as standard care after the end of ASSERT</measure>
    <time_frame>November 2005</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the various treatment regimens after the end of ASSERT of the participating AS patients in various countries</measure>
    <time_frame>November 2005</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of spinal inflammation analyzed by MRI after discontinuation of infliximab and 4-8 weeks and 2 and 4 years after re-treatment</measure>
    <time_frame>November 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy of infliximab over 4 and 6 years of therapy measured by the ASAS response criteria</measure>
    <time_frame>November 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and safety of a new start of infliximab therapy after discontinuation for several months after 2 and 4 years of continuous treatment</measure>
    <time_frame>November 2008 and November 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term effects on QoL</measure>
    <time_frame>November 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term effects on health resource utilisation and productivity in paid and unpaid work</measure>
    <time_frame>November 2010</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>infliximab</intervention_name>
    <description>Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients in Europe who have completed visit &quot;week 96&quot; of ASSERT (last infusion of
             infliximab)

          -  Capacity to understand and sign an informed consent form

          -  Capacity to read and understand subject assessment forms

          -  Using adequate birth control measures for the duration of the study and for 6 months
             after receiving the last infusion, if the patient is of childbearing potential

          -  Serum creatinine &lt; 1,4 mg/dl

          -  Hemoglobin &gt; 9,0 mg /dl for males and &gt; 8,5 mg/dl for females

          -  Serum transaminase levels within 3 times the upper limit of normal range

        Exclusion Criteria:

          -  Have used systemic prednisolone &gt; 20 mg during the 2 weeks prior to screening

          -  Have used cytotoxic drugs after the end of ASSERT including chlorambucil,
             cyclophosphamide and alkylating agents

          -  Have received any previous treatment with etanercept or any other anti-TNF agent
             (other than infliximab) after the end of the ASSERT trial

          -  General medical exclusion criteria

          -  Use of any investigational drug within 30 days prio to screening

          -  Concomitant diagnosis or history of congestive heart failure

          -  History of latent or active tuberculosis

          -  Signs or symptoms suggestive of active tuberculosis

          -  Recent close contact with a person with active tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Braun, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumazentrum Ruhrgebiet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jürgen Braun, Prof. Dr.</last_name>
    <phone>+49 (0) 2325 592131</phone>
    <email>j.braun@rheumazentrum-ruhrgebiet.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Heldmann, Dr. med.</last_name>
    <phone>+ 49 (0) 2325 592138</phone>
    <email>heldmann@rheumazentrum-ruhrgebiet.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Steinfeld, Prof. Dr.</last_name>
      <phone>+32 (0) 25 556 745</phone>
      <email>ssteinfe@ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Serge Steinfeld, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limburg University Centre</name>
      <address>
        <city>Diepenbeek</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piet Geusens, Prof. Dr.</last_name>
      <phone>+32 (0) 89 362977</phone>
      <email>piet.geusens@ping.be</email>
    </contact>
    <investigator>
      <last_name>Piet Geusens, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis, Afdeling Rheumatologie</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Van den Bosch, Dr.</last_name>
      <email>filip.vandenbosch@skynet.be</email>
    </contact>
    <investigator>
      <last_name>Filip van den Bosch, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt de Vlam, Dr.</last_name>
      <phone>+32 (0) 16 332 211</phone>
      <email>kurt.devlam@pi.be</email>
    </contact>
    <contact_backup>
      <last_name>Rene Westhovens, Prof. Dr.</last_name>
      <phone>+32 (0) 16 344 792</phone>
      <email>rene.westhovens@uz.kuleuven.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Rene Westhovens, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Central Hospital, Division of Rheumatology</name>
      <address>
        <city>Helsinki</city>
        <zip>00029HYKS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjatta Leirisalo-Repo, Prof</last_name>
      <email>Marjatta.Leirisalo-Repo@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Marjatta Leirisalo-Repo, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hopitalier Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime Breban, Prof.Dr.</last_name>
      <phone>+33 (0) 1 49095672</phone>
      <email>maxime.breban@cch.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Maxime Breban, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat R. Descartes, Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Kolta, Dr.</last_name>
      <phone>+33 (0) 1 5841 2584</phone>
      <email>sami.kolta@cch.ap-hop-paris.fr</email>
    </contact>
    <contact_backup>
      <last_name>Maxime Dougados, Prof.Dr.</last_name>
      <phone>+33 (0) 1 5841 2562</phone>
      <email>m-doug@cch.ap-hop-paris.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Maxime Dougados, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd Burmester, Prof. Dr.</last_name>
      <phone>+49 (0) 30 45051 3082</phone>
      <email>gerd.burmester@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Bettina Marsmann</last_name>
      <phone>+49 (0) 30 45051 3025</phone>
      <email>bettina.marsmann@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gerd Burmester, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite Klinikum Steglitz</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Brandt, Dr.</last_name>
      <phone>+49 (0) 30 8445 4414</phone>
      <email>henning.brandt@charite.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Sieper, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Heldmann, Dr.</last_name>
      <phone>+49 (0) 2325 592138</phone>
      <email>heldmann@rheumazentrum-ruhrgebiet.de</email>
    </contact>
    <contact_backup>
      <last_name>Jürgen Braun, Prof. Dr.</last_name>
      <phone>+49 (0) 2325 592 131</phone>
      <email>j.braun@rheumazentrum-ruhrgebiet.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jürgen Braun, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ludwigs-Maximilian-Universität</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Strasser</last_name>
      <phone>+49 (0) 89 51603511</phone>
      <email>Christine.Strasser@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Schewe, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Gruenke, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I.E van der Horst-Bruinsma, Dr.</last_name>
      <phone>+31 (0) 20 4443432</phone>
      <email>IE.vanderHorst@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>B.A.C Dijkmans, Prof.Dr.</last_name>
      <phone>+31 (0) 20 4443432</phone>
      <email>bac.dijkmans@vumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>B.A.C Dijkmans, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelies Boonen</last_name>
      <phone>+ 31 (0) 43 388 42 33</phone>
      <email>aboo@sint.azm.nl</email>
    </contact>
    <contact_backup>
      <last_name>Robert Landewe, Prof. Dr.</last_name>
      <phone>+31 (0) 43 387 7010</phone>
      <email>Rlan@sint.azm.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Landewe, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cambridge/ Clin Med</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hill Gaston, Prof. Dr.</last_name>
      <phone>+44 (0) 1233 330161</phone>
      <email>jshg2@medschl.cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Hill Gaston, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9N2</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrs. Keen, Dr.</last_name>
      <phone>+44 (0) 113 392 24848</phone>
    </contact>
    <contact_backup>
      <last_name>Paul Emery, Prof.Dr.</last_name>
      <phone>+44 (0) 113 392 5068</phone>
      <email>p.emery@leeds.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Emery, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2005</study_first_submitted>
  <study_first_submitted_qc>October 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>May 30, 2008</last_update_submitted>
  <last_update_submitted_qc>May 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Jürgen Braun</name_title>
    <organization>Rheumazentrum Ruhrgebiet</organization>
  </responsible_party>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Long-term therapy with infliximab</keyword>
  <keyword>Radiographic progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

